Circassia’s Cat-SPIRE Sinks in Phase 3 Trial

Circassia Pharmaceuticals’ candidate for patients allergic to cats — synthetic peptide immuno-regulatory epitopes — failed in a Phase 3 study, missing its primary endpoint of superiority to placebo in subjects aged 12 to 65 years.

In a clinical trial evaluating 1,245 subjects, the Cat-SPIRE candidate reduced allergy symptoms in almost 60 percent of patients versus placebo at 58.5 percent.

Moving forward, the company will focus on advancing its NIOX asthma management products.